Brazil’s Medtechs Look To Solutions After 50% US Tariff Hit Amid ‘Scenario Of Uncertainty’

Brazil Handed Steepest Tariff Rise Despite Large US Medtech Trade Surplus

 
• By Bernard Murphy
  
Brazil's ABIMO reflects on response to to unprecedented US tariffs (Shutterstock)

More from Policy & Regulation

More from Medtech Insight